Speech-Language Pathologists in Amston, CT Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Bloom Speech Therapy, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 92 Senate Brook Dr, Amston, CT 06231 Phone: 860-685-0819 |
 Jocelyn Knight, M.A.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 Congress Dr, Amston, CT 06231 Phone: 860-531-8073 |
Amston Speech-language Pathology, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 Congress Dr, Amston, CT 06231 Phone: 203-895-5650 |
News Archive
House unanimously passes bill to revamp VA care
The measure would allow vets to seek private care if they couldn't be seen quickly by the VA and requires an evaluation of the VA health system.
Study looks at differences in brain structure between karate practitioners
Brain scans have revealed distinctive features in the brain structure of karate experts, which could be linked to their ability to punch powerfully from close range. Researchers from Imperial College London and UCL (University College London) found that differences in the structure of white matter - the connections between brain regions - were correlated with how black belts and novices performed in a test of punching ability.
Palliative care for stroke affected by age, gender, stroke type
Whether patients with stroke are referred to palliative care services depends on their age, their gender, and what type of stroke they have had, Australian study results indicate.
International Stem Cell signs definitive agreement with Socius CG II
International Stem Cell Corporation, www.intlstemcell.com, today announced it has entered into a definitive agreement dated May 4, 2010 with Socius CG II, Ltd., pursuant to which Socius has committed to purchase a single tranche of up to $10 million in non-convertible Series F Preferred Stock from ISCO.
Janssen's NUCYNTA ER tablets more effective in providing pain management in adults with DPN
Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.
› Verified 9 days ago